Olfr739, encoded by the Or11g1 gene, is an olfactory receptor in mice that functions as a G-protein-coupled receptor (GPCR). This receptor type is integral in the detection of odorant molecules and initiating neuronal responses that lead to the perception of smell. The unique architecture of these receptors, featuring seven transmembrane domains, allows for the recognition of a wide range of odorant molecules and the subsequent activation of G protein-mediated signaling cascades. These cascades involve various secondary messengers and lead to a series of cellular responses that culminate in the perception of smell. The inhibition of Olfr739, and olfactory receptors in general, is a complex process given their indirect interactions with various cellular and molecular pathways. As GPCRs, these receptors can be influenced by the levels of secondary messengers such as cyclic AMP (cAMP). Compounds that modulate cAMP levels, either by stimulating its production (like forskolin) or preventing its degradation (such as caffeine or vinpocetine), can lead to changes in receptor activity. An increase in cAMP can result in receptor desensitization or downregulation, thereby reducing the receptor's response to its ligand. Additionally, changes in the neurochemical environment, influenced by neurotransmitter availability or receptor dynamics, can also impact GPCR function. For instance, compounds altering neurotransmitter levels (like reserpine) or blocking specific neurotransmitter receptors (such as atropine) can indirectly affect GPCR signaling.
Moreover, the overall excitability and signaling of neurons, crucial for the initiation and propagation of GPCR-mediated responses, can be modulated by various ion channel blockers. Compounds like lidocaine and tetrodotoxin, which block sodium channels, or calcium channel blockers like verapamil and diltiazem, can alter neuronal action potentials and, consequently, the functional dynamics of GPCRs including Olfr739. In summary, the potential inhibition of Olfr739 involves a multifaceted approach targeting different aspects of GPCR signaling and neuronal function. This includes manipulating cAMP levels, altering neurotransmitter systems, and modulating ion channel activities. Understanding these complex interactions is key to exploring potential indirect methods to modulate the activity of olfactory receptors like Olfr739.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cAMP levels. Elevated cAMP might lead to a compensatory downregulation or desensitization of GPCRs, including Olfr739, reducing its response to odorants. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 5 g 100 g 250 g 1 kg 5 kg | $32.00 $66.00 $95.00 $188.00 $760.00 | 13 | |
Caffeine is a known phosphodiesterase inhibitor, which leads to an increase in cAMP levels. This elevation could potentially desensitize GPCR responses, including those mediated by Olfr739, due to prolonged activation. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is another phosphodiesterase inhibitor, elevating cAMP levels. Increased cAMP could indirectly lead to reduced Olfr739 activity through receptor desensitization. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram specifically inhibits phosphodiesterase-4, increasing cAMP in specific tissues. This might indirectly affect Olfr739 by altering the GPCR response dynamics due to cAMP modulation. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $50.00 $128.00 | ||
Lidocaine, a sodium channel blocker, could indirectly influence GPCR signaling, including Olfr739, by modulating neuronal excitability and potentially altering the olfactory signal transduction. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride, a diuretic affecting sodium channels and transporters, might indirectly influence Olfr739 by altering ionic balances, which can affect neuron excitability and GPCR signal transduction. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, could indirectly affect Olfr739 by inducing cAMP production and potentially causing receptor desensitization due to prolonged GPCR activation. | ||||||
Reserpine | 50-55-5 | sc-203370 sc-203370A | 1 g 5 g | $134.00 $406.00 | 1 | |
Reserpine, an inhibitor of the vesicular monoamine transporter, can deplete neurotransmitters and might indirectly influence Olfr739 by altering the neurochemical environment of olfactory neurons. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $200.00 | 2 | |
Atropine, a muscarinic acetylcholine receptor antagonist, can indirectly affect GPCR signaling including Olfr739 by altering acetylcholine-mediated signaling pathways in the nervous system. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil, a calcium channel blocker, might indirectly influence Olfr739 by altering calcium-dependent signaling pathways, which are integral in neuron function and potentially GPCR signaling. | ||||||